Bone Marrow Transplant
Palliative Care Support for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant
Feasibility of Implementing Pre-Transplant Palliative Care Support for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies
|Closed||Hematologic Malignancies||Pilot Study||
This pilot clinical trial studies palliative care support for patients with hematological malignancies undergoing hematopoietic cell transplant. Palliative care support may improve quality of life in this patient population.
Eligibility Criteria (must meet the following to participate in this study)
- Written informed consent
- English as primary language
- Planned autologous or allogeneic hematopoietic cell transplantation
- Presence of co-morbidities (hematopoietic cell transplant co-morbidity index [HCT-CI] score 3 or greater), high risk disease (relapse risk > 25%), or a planned type of transplant (human leukocyte antigen [HLA]-mismatched allogeneic or myeloablative) that places the patient at a higher than average risk of non-relapse mortality or relapse
Exclusions (conditions that would prevent participation in this study)
- Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team
- First transplant of a planned tandem procedure (the second transplant is eligible)
Last UpdatedSeptember 18, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.